DPP-4 Inhibitors: Impact on glycemic control and cardiovascular risk factors

Diabetes Care

Volumn 34, Issue SUPPL. 2, 2011, Pages

  Dicker, Dror ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENALAPRIL; EXENDIN 4; GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; LIRAGLUTIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; TRIACYLGLYCEROL; VILDAGLIPTIN; ADAMANTANE; DIPEPTIDE; DRUG DERIVATIVE; NITRILE; PYRROLIDINE DERIVATIVE;

ABDOMINAL OBESITY; ACUTE HEART INFARCTION; ANGIONEUROTIC EDEMA; BODY WEIGHT; CALORIC INTAKE; CARDIOVASCULAR RISK; COUGHING; DISEASE SEVERITY; DIZZINESS; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FACE EDEMA; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; INCIDENCE; KIDNEY FAILURE; LOW DRUG DOSE; METABOLIC SYNDROME X; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREATITIS; PERIPHERAL EDEMA; REVIEW; RHINOPHARYNGITIS; RISK FACTOR; SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VOMITING; CARDIOVASCULAR DISEASE;

ADAMANTANE; CARDIOVASCULAR DISEASES; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; NITRILES; PYRROLIDINES; RISK FACTORS;

EID: 79959773411     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-s229     Document Type: Review

References (18)

1. Davidson JA. Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. Cleve Clin J Med 2009;76(Suppl. 5):S28-S38
2. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007;298:194-206 (Pubitemid 47057766)
3. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007;30:1979-1987 (Pubitemid 47219404)
4. Williams-Herman D, Round E, Swern AS, et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord 2008;8:14
5. U.S. Food and Drug Administration. Information for healthcare professionals: acute pancreatitis and sitagliptin (marketed as Januvia and Janumet) [Internet], 2009. Available from http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm183764. Accessed 14 January 2010
6. Anon. New galvus clinical data reinforces efficacy profile; safety update provided to regulatory agencies [Internet]. Available from http://cws. huginonline.com/N/134323/PR/200711/1166139-5-2.html. Accessed 12 November 2007
7. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696-1705 (Pubitemid 46048557)
8. Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010;122:16-27
9. Sauvé M, Ban K, Momen MA, et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 2010;59:1063-1073
10. Ye Y, Keyes KT, Zhang C, Perez-Polo JR, Lin Y, Birnbaum Y. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol 2010;298:H1454-H1465
11. Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging 2010;3:195-201
12. Mistry GC, Maes AL, Lasseter KC, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 2008;48:592-598 (Pubitemid 351503521)
13. Marney A, Kunchakarra S, Byrne L, Brown NJ. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension 2010;56:728-733
14. Matikainen N, Mänttäri S, Schweizer A, et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006;49:2049-2057 (Pubitemid 44168471)
15. Boschmann M, Engeli S, Dobberstein K, et al. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab 2009;94:846-852
16. Hsieh J, Longuet C, Baker CL, et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 2010;53:552-561
17. DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008;24:2943-2952
18. Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447-1456